Alumis (NASDAQ:ALMS) Receives “Buy” Rating from HC Wainwright

Alumis (NASDAQ:ALMS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 275.00% from the stock’s current price. HC Wainwright also issued estimates for Alumis’ Q1 2025 earnings at ($1.29) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

A number of other research firms also recently weighed in on ALMS. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Alumis Price Performance

ALMS opened at $4.00 on Wednesday. The business has a 50 day moving average of $5.55 and a 200-day moving average of $8.43. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.

Institutional Trading of Alumis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in Alumis in the third quarter valued at approximately $27,000. Wells Fargo & Company MN lifted its stake in shares of Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Alumis in the 4th quarter worth $79,000. MetLife Investment Management LLC acquired a new stake in shares of Alumis during the third quarter worth $89,000. Finally, Marshall Wace LLP bought a new stake in Alumis in the fourth quarter valued at about $108,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.